Variable | Univariate analysis | P | Multivariate analysis | Â | |
---|---|---|---|---|---|
 | No. of patients (%) a |  | OR (95% CI) | Pf | |
 | Absence | Presence |  |  |  |
 | (n = 69) | (n = 26) |  |  |  |
Age (years) | |||||
 Median [range] | 68 [37–87] | 68 [55–83] | 0.565 d |  |  |
 <  75 | 57 (83) | 21 (81) | 1.000 e |  |  |
 ≥ 75 | 12 (17) | 5 (19) |  |  |  |
Sex | |||||
 Male | 40 (58) | 10 (39) | 0.109 e | 2.032 (0.787–5.248) | 0.143 |
 Female | 29 (42) | 16 (62) |  |  |  |
ECOG PS | |||||
 0–1 | 60 (87) | 24 (92) | 0.722 e |  |  |
 2–3 | 9 (13) | 2 (8.0) |  |  |  |
Stage | |||||
 I-III | 26 (38) | 10 (39) | 1.000 e |  |  |
 IV | 43 (62) | 16 (62) |  |  |  |
BSA (m2) | |||||
 Median [range] | 1.6 [1.1–2.0] | 1.6 [1.3–1.9] | 0.478 d |  |  |
 <  1.6 | 39 (57) | 15 (58) | 1.000 e |  |  |
 ≥ 1.6 | 30 (43) | 11 (42) |  |  |  |
BMI (kg/m2) | |||||
 Median [range] | 22.1 [15.3–30.3] | 21.4 [16.8–29.1] | 0.652 d |  |  |
 < BMI 25 | 59 (86) | 22 (85) | 1.000 e |  |  |
 ≥ BMI 25 | 10 (15) | 4 (15) |  |  |  |
Recurrence | |||||
 Yes | 23 (33) | 11 (42) | 0.475 e |  |  |
 No | 46 (67) | 15 (58) |  |  |  |
Metastasis | |||||
 Yes | 64 (93) | 24 (92) | 1.000 e |  |  |
 No | 5 (7) | 2 (8.0) |  |  |  |
Line of therapy | |||||
 First line | 18 (26) | 8 (31) | 0.797 e |  |  |
 Second line and later line | 51 (74) | 18 (69) |  |  |  |
EGFR mutation | |||||
 Exon 19 Deletion | |||||
  Yes | 24 (35) | 10 (39) | 0.812 e |  |  |
  No | 45 (65) | 16 (62) |  |  |  |
 Exon 21 L858R point mutation | |||||
  Yes | 27 (39) | 11 (42) | 0.817 e |  |  |
  No | 42 (60) | 15 (58) |  |  |  |
Smoking history | |||||
 Yes | 36 (52) | 10 (39) | 0.258 e |  |  |
 No | 33 (48) | 16 (62) |  |  |  |
Grade 1 liver dysfunction b | |||||
 Yes | 21 (30) | 10 (38) | 0.471 e |  |  |
 No | 48 (70) | 16 (62) |  |  |  |
Concomitant medication c | |||||
 AS |  |  |  |  |  |
  Yes | 40 (58) | 8 (31) | 0.022 e | 0.341 (0.129–0.900) | 0.030 |
  No | 29 (42) | 18 (69) |  |  |  |
CYP1A2 inducer | |||||
 Yes | 2 (3.0) | 0 (0.0) | 1.000 e |  |  |
 No | 67 (97) | 26 (100) |  |  |  |
CYP3A4 inducer | |||||
 Yes | 2 (3.0) | 0 (0.0) | 1.000 e |  |  |
 No | 67 (97) | 26 (100) |  |  |  |
CYP3A4 inhibitor | |||||
 Yes | 5 (7.0) | 1 (4.0) | 1.000 e |  |  |
 No | 64 (93) | 25 (96) |  |  |  |